Patterns in public records, tested
FDA & biotech strategies
Strategies built on FDA approvals, drug trials and device filings, each with its honest grade from past tests — including the ones that don't work.
Filtered to FDA & biotech · Clear filters
Browse the strategiesUpdated Oct 17
A strategy’s big number is its edge over similar stocks in past tests; the smaller line is its average return over the stated hold (monthly strategies show an average month). Weekly Top 10 shows its total tracked return. Hypothetical results — not investment advice.
More filters · 1 changed
Selling short uses borrowed shares to try to profit from a falling price.
No rule has passed the publication check yet — here is what it takes
All strategies
Showing 1 of 23 strategies · FDA & biotech · short sales
Sell short after an FDA clinical holdSell When the FDA Puts a Trial on HoldDirection: Sell short Research onlyNot yet validatedvs shorting similar stocks+4.4 pp−0.3% avg. short return over 3 months, past tests
Sell short when it fires · close it 3 months later
Selling short uses borrowed shares to try to profit from a falling price.
Research, not proof: the rule has not passed every check yet, including one on new trades.
Test sequence
- Sell short when it fires
- Hold 3 months
- Close it 3 months later
In past tests · each short position held 3 months
- Selling each stock short made
- −0.3%
- on average
- Vs selling similar stocks short
- 4.4
- percentage points better than selling similar stocks short
- Made money in
- 107 of 222
- tries (48%)
8 open now · next buy-back Sep 21 · Company filings
Explore strategy ShareGo deeper
Hypothetical, not investment advice. Each position is opened at the next trading day’s close after the record became public and held for the stated time. Sell short ideas assume borrowed shares are sold, then bought back to close. Past results do not predict future results.